கோவிட் ஷீல்டு இரண்டாவது தவணை தடுப்பூசி செலுத்த கால அவகாசம் ஆறிலிருந்து எட்டு வாரங்களாக உயர்த்தி மத்திய அரசு உத்தரவு.

கோவிட் ஷீல்டு இரண்டாவது தவணை தடுப்பூசி செலுத்த கால அவகாசம் ஆறிலிருந்து எட்டு வாரங்களாக உயர்த்தி  மத்திய அரசு உத்தரவு.

PRESS INFORMATION BUREAU GOVERNMENT OF INDIA 

Centre writes to States/UTs to Increase the Interval between two doses of COVISHIELD to 6-8 weeks based on NTAGI and NEGVAC Recommendation 

MOST READ  தேர்தல் 'மை'யை அழிக்க முடியாதது ஏன்?

Protection enhanced if the second dose of COVISHIELD is administered between 6-8 weeks 

New Delhi, 22nd March, 2021 

In view of the emerging scientific evidence, the interval between two doses of a specific COVID-19 vaccine i.e. COVISHIELD, has been revisited by National Technical Advisory Group on Immunization (NTAGI) and subsequently by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) in its 20th meeting. During this meeting the recommendation has been revised to provide 2nd dose of COVISHIELD at 4-8 weeks' interval after the 1st dose, instead of earlier practiced interval of 4-6 weeks. This decision of revised time interval between two doses is applicable ONLY to COVISHIELD and NOT to COVAXIN Vaccine. 

MOST READ முப்படைகளில் 1.07 லட்சம் பணியிடங்கள் காலி - மத்திய அரசு தகவல்

In a letter written by the Union Health Secretary Shri Rajesh Bhushan to the Chief Secretaries of States/UTs today, he has noted that the Ministry of Health and Family Welfare, Government of India has accepted the recommendations of NTAGI and NEGVAC and has thereafter advised the States and UTs to ensure the administration of 2nd dose of COVISHIELD to beneficiaries within this stipulated time interval of 4-8 weeks after 1st dose. 

MOST READ தமிழகத்தின் தென் மாவட்டங்களில் மிதமான மழைக்கு வாய்ப்பு - வானிலை மையம் தகவல்

Keeping the existing scientific evidence in view, it appears that protection is enhanced if the second dose of COVISHIELD is administered between 6-8 weeks, but not later than stipulated period of 8 weeks. The Union Health Secretary has urged the States and UTs to instruct the concerned officials accordingly to undertake necessary steps to widely disseminate the message of revised dosing interval amongst programme managers, vaccinators and recipients of COVISHIELD vaccine and ensure adherence of the revised dosing interval.